

## YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU:

- ✓ 18 years of age or older
- ✓ Possess a valid personal email address
- ✓ Be an Active-Duty Member of the United States Air Force, or a retiree of the United States Air Force, or the spouse of an active duty member or retiree of the United States Air Force
- ✓ Have a DoD medical record (current AHLTA record)
- ✓ Be a TRICARE Prime beneficiary
- ✓ Be Defense Enrollment Eligibility Reporting System (DEERS) eligible
- ✓ Be enrolled at a United States Military Treatment Facility

\*Spouses of Active-Duty members and retirees of the USAF must be TRICARE Prime beneficiaries

The Coriell Personalized Medicine Collaborative (CPMC) is conducting a research study sponsored by the United States Air Force to learn whether giving people personal genetic information about potentially actionable medical conditions or drug response can improve their health or change their behavior.

**Participants will receive personal genomic information related to drug response and potentially actionable medical conditions such as coronary artery disease. Participation involves providing a saliva sample and completion of online surveys. No monetary compensation will be provided.**

This research has been approved by the Air Force Research Laboratory Institutional Review Board in accordance with AFI 40-402, under protocol # F-WR-20110046.

## INFLUENCING SCIENCE AND MEDICINE

The CPMC has been recognized by the **United States Department of Health and Human Services** and **MIT Technology Review** as leading the way in personalized medicine. In addition, investigators from the CPMC have published in nationally recognized journals including *Personalized Medicine* and *Genetics in Medicine* and have presented study findings at major medical and scientific conferences such as the National Summit on Personalized Medicine, American Pharmacists Association Annual Meeting, American Society for Human Genetics Conference, Mt. Sinai Institute for Personalized Medicine Distinguished Lecturers Series, Consumer Genetics Conference, and American College of Medical Genetics Annual Meeting.



**CORIELL  
INSTITUTE**  
FOR MEDICAL RESEARCH

Coriell Institute for Medical Research  
403 Haddon Avenue  
Camden, New Jersey 08103

888-580-8028 | phone  
856-964-0254 | fax  
cpmcweb@coriell.org | email

[www.usaf.coriell.org](http://www.usaf.coriell.org)

BE A PART OF  
A PERSONALIZED MEDICINE  
RESEARCH STUDY

Part of the Air Force Personalized Medicine Program

Sponsored by the United States Air Force



# CORIELL PERSONALIZED MEDICINE COLLABORATIVE

## ABOUT THE STUDY

The Coriell Personalized Medicine Collaborative (CPMC) Clinical Utility study is a part of the Air Force Personalized Medicine Program. This research program is a forward thinking, multi-party effort involving volunteer study participants, medical professionals, scientists, ethicists, genetic counselors, pharmacists, and information technology experts whose goal is to **evaluate the utility of genome-informed medicine** when implemented in an ethical, legal and responsible format.

## STUDY AIMS

To determine if reporting genetic variation related to complex disease and drug metabolism directly to research study participants results in changes in participant health and/or health behavior.

## SECONDARY AIMS

To look for changes in genes which increase the risk of certain diseases;

To look at how genetic changes interact with the environment to play a role in disease risk;

To study how genetic variants may affect the way certain medicines work.



Individuals interested in enrolling in the CPMC must watch an online informed consent presentation or attend a session in person to learn about the research study. Those who choose to enroll sign an informed consent document and submit a saliva sample for DNA analysis.

After enrolling, participants will be prompted to activate a secure personal CPMC web portal account. This account will be used **to complete online questionnaires about their family and personal medical histories, lifestyle, diet, and demographics**. Once complete, an individual's saliva sample is released for DNA analysis in Coriell's CLIA-certified Genotyping and Microarray Center. The sample is tested on the Affymetrix 6.0 GeneChip and the DMET Plus drug metabolism platforms for sites of genetic variation that have been associated with common complex diseases (e.g. coronary artery disease) and drug metabolism.

Once testing is complete, study participants are given **access to personalized results** for select health conditions and medication response.

Personalized results are based on the genetic analysis and other risk factors including family history and lifestyle. New results are provided to all participants as additional conditions and drug-gene pairs are added to the study.

Participants have the opportunity to speak with Coriell's genetic counselors at no cost to discuss their CPMC study results. A variety of **educational materials are provided** for participants on the web portal. In addition, educational forums are held regularly regarding personalized medicine and the specific conditions reported by the CPMC research study. Videos of these sessions are made available online within weeks of the event.

Following the release of results, participants are queried at regular intervals to determine whether receipt of genomic information influenced their medical care, personal health decisions, and ultimately their overall health.

Medical encounter data are combined with genomic information from the study, and then stripped of identifying demographics. The de-identified dataset is used to look for associations between genes, environment, and disease risk as well as the impact of genetic information on medication use and dosage.

Together, medical records and surveys contribute to **outcomes data** which are used to establish the potential benefit of genome-informed medicine.